Drug intelligence / Profile preview

Frilabiol Circulation

Development stage: Unknown
Lead developer: FRiLAB
Modality: Small Molecules
Administration: Oral

Overview

Frilabiol Circulation is a phytotherapy-based food supplement developed by the Swiss pharmaceutical company FRiLAB (Frilab Laboratories). It is designed to address circulatory problems and the sensation of heavy legs through a 'triple formulation' approach. The product is administered orally and utilizes an innovative pharmaceutical dosage form intended to provide rapid action and a prolonged effect. As a nutraceutical, it is marketed as part of FRiLAB's Frilabiol product line, focusing on venous health and symptom relief.

Brand names: Frilabiol Circulation

Beyond the preview

Go deeper on Frilabiol Circulation.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frilabiol Circulation.

Explore the full profile